Creo Medical Group First Half 2024 Earnings: UK£0.034 loss per share (vs UK£0.044 loss in 1H 2023)

Creo Medical Group (LON:CREO) First Half 2024 Results

Key Financial Results

• Revenue: UK£15.2m (down 3.2% from 1H 2023).
• Net loss: UK£12.3m (loss widened by 6.0% from 1H 2023).
• UK£0.034 loss per share.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Creo Medical Group Earnings Insights

Looking ahead, revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in the United Kingdom.

Performance of the British Medical Equipment industry.

The company's shares are down 23% from a week ago.

Risk Analysis

Be aware that Creo Medical Group is showing 4 warning signs in our investment analysis and 1 of those doesn't sit too well with us...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.